NCT04698941View on ClinicalTrials.gov

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 25, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2022

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Albumin Paclitaxel

Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.

DRUG

Simvastatin

20mg daily oral tablet taken.

Trial Locations (2)

200031

RECRUITING

CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai

200433

RECRUITING

Shanghai pulmonary hospital, Tongji University, Shanghai

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Sciences

OTHER_GOV

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT04698941 - Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | Biotech Hunter | Biotech Hunter